Investing in Neuroscience: A Deep Dive into Jazz Pharmaceuticals vs. Harmony Biosciences

In the rapidly evolving field of neuroscience, particularly in the treatment of sleep disorders, two companies have distinguished themselves as frontrunners—Jazz Pharmaceuticals (JAZZ) and Harmony Biosciences (HRMY). Both companies have developed significant drug portfolios, but their approaches to market dominance and growth are markedly different. In this article, we will assess their individual strengths, weaknesses, and investment potential to help you decide which stock may be a better pick.

The Investment Case for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals stands tall with over two-thirds of its revenue stemming from its neuroscience division. Their flagship product, Xywav, is an oral medication that addresses multiple conditions associated with narcolepsy, such as excessive daytime sleepiness (EDS) and cataplexy, while also being low-sodium. This unique attribute eliminates the risks associated with high sodium intake, marking Xywav as the sole FDA-approved oxybate therapy without such warnings. In 2024, sales for Xywav surged 16% year-over-year, reaching an impressive $1.5 billion.

Another cornerstone of Jazz’s portfolio is Epidiolex, a cannabidiol (CBD) medication that treats specific types of seizures related to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The sales for Epidiolex grew by 15% year-over-year, amounting to $972 million in 2024, bolstering its neuroscience revenue and diminishing reliance on the oxybate franchise. Epidiolex is poised to achieve blockbuster status by 2025.

Moreover, Jazz boasts a diverse lineup that includes five oncology drugs, contributing to 29% of their 2024 product revenues. The company is actively looking to further its oncology offerings by acquiring Chimerix for $935 million, which may introduce the forthcoming drug dordaviprone, aimed at treating glioma cases. However, not all news is positive; Jazz has recently discontinued the development of suvecaltamide due to unsatisfactory trial results in essential tremors and Parkinson’s disease.

Jazz Pharmaceuticals Financial Overview

In 2024, Jazz reported a revenue increase of 6% year-over-year, totaling $4.1 billion. With a strong cash reserve of $3 billion, Jazz projects a rise in sales of $4.15-$4.40 billion in 2025, indicating steady growth ahead.

The Case for Harmony Biosciences (HRMY)

On the other hand, Harmony Biosciences is distinguished by its flagship product, Wakix, which is the only FDA-approved therapy for narcolepsy that is not classified as a controlled substance. This key offering has rapidly gained traction, leading to a substantial 23% increase in 2024 sales, amounting to $715 million. Harmony expects an upward trend, forecasting 2025 sales between $820-$860 million, which would denote an 18% growth.

However, Harmony faces a critical turning point as it approaches the potential loss of exclusivity for Wakix by the end of the decade. To mitigate risks, the company is in the late stages of development for two next-generation formulations of its drug—pitolisant Gastro-Resistant and pitolisant High-Dose.

Additionally, Harmony is making strides in the cannabis sector, having acquired Zynerba Pharmaceuticals. Their lead pipeline drug, ZYN-002, is currently undergoing evaluation for its efficacy in treating Fragile X Syndrome, with data expected in Q3 2025.

Harmony Biosciences Financial Overview

Harmony’s financial health indicates a cash balance of $576 million as of 2024. Still, it must be cautious with its reliance on a single flagship product as this presents a concentration risk.

Financial Projections: Jazz vs. Harmony

Jazz Pharmaceuticals is set to witness a 6% increase in sales with a 12% rise in earnings per share (EPS) in 2025. Notably, EPS estimates have been on an upward trajectory for both 2025 and 2026.

In contrast, Harmony Biosciences anticipates an 18% sales increase and a 16% uptick in EPS for the same period. However, their EPS estimates have seen a downward trend recently.

Stock Performance and Valuation Comparison

Year to date, both JAZZ and HRMY experienced a loss of about 17%, compared to the industry average decline of 8%. From a valuation perspective, Unity is currently rated higher than Jazz, trading at forward earnings of 8.63 compared to Jazz’s 5.07. However, both stocks are trading at relative discounts amid challenging market conditions.

Conclusion: Which Stock is the Better Pick? Jazz or Harmony?

Upon analysis, while both companies exhibit solid performance metrics, Jazz Pharmaceuticals appears to be the more favorable investment opportunity. Harmony’s growth is promising, yet its dependency on a single product introduces significant risk. In contrast, Jazz offers a diversified portfolio, an impressive track record of consistent sales growth, and robust EPS forecasts. Additionally, the company maintains a stronger cash reserve and an attractive valuation, reinforcing its potential as a valuable investment for 2025 and beyond. Jazz currently holds a Zacks Rank of #2 (Buy), whereas Harmony is labeled with a Zacks Rank of #3 (Hold). This further solidifies Jazz’s competitive advantage in today’s market.

For further insights and updates on the stock market, be sure to check out more analyses and articles from Zacks Investment Research.